DSpace
 

EPrints@IIT Delhi >
Faculty Research Publicatons  >
Biomedical Engineering [CBME] >

Please use this identifier to cite or link to this item: http://eprint.iitd.ac.in/handle/2074/593

Full metadata record

DC FieldValueLanguage
dc.contributor.authorGuha, Sujoy K-
dc.contributor.authorSingh, Gulshanjit-
dc.contributor.authorSrivastava, Anil-
dc.contributor.authorDas, H C-
dc.contributor.authorBhardwaj, J C-
dc.contributor.authorMathur, Vineet-
dc.contributor.authorKoul, Veena-
dc.contributor.authorMalhotra, R L-
dc.contributor.authorDas, S K-
dc.date.accessioned2005-07-28T08:53:45Z-
dc.date.available2005-07-28T08:53:45Z-
dc.date.issued1998-
dc.identifier.citationContraception, 58(3), 165–174en
dc.identifier.urihttp://eprint.iitd.ac.in/dspace/handle/2074/593-
dc.description.abstractContraceptive action of a single intra–vas deferens injection of a specific preparation of styrene maleic anhydride (SMA) dissolved in dimethyl sulphoxide, forming a drug given the name Risugt, has been demonstrated earlier.Now fertility control over a 2-year period with doses having the SMA component ranging from 40 to 70 mg is reported here. The results suggest that pregnancy protection is obtained both in the azoospermic and non-azoospermic states. Side effects are minimal and transient in nature. Libido remains unaltered.en
dc.format.extent2010152 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.subjectsingle injectionen
dc.subjectvas deferensen
dc.subjectmaleen
dc.subjectpregnancy protectionen
dc.subjectlibido maintenanceen
dc.titleTwo-year clinical efficacy trial with dose variations of a vas deferens injectable contraceptive for the maleen
dc.typeArticleen
Appears in Collections:Biomedical Engineering [CBME]

Files in This Item:

File Description SizeFormat
guhatwo1998.pdf1.96 MBAdobe PDFView/Open
View Statistics

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback